Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Groen HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJM, Hoekstra O, Schramel FMNH, van der Noort V, van Tinteren H, Smit EF, Dingemans AC; NVALT Study Group, the Netherlands. Groen HJM, et al. Br J Cancer. 2019 Aug;121(5):372-377. doi: 10.1038/s41416-019-0533-3. Epub 2019 Jul 24. Br J Cancer. 2019. PMID: 31337877 Free PMC article. Clinical Trial.
Costs of non-small cell lung cancer in the Netherlands.
van der Linden N, Bongers ML, Coupé VM, Smit EF, Groen HJ, Welling A, Schramel FM, Uyl-de Groot CA. van der Linden N, et al. Among authors: schramel fm. Lung Cancer. 2016 Jan;91:79-88. doi: 10.1016/j.lungcan.2015.10.015. Epub 2015 Oct 17. Lung Cancer. 2016. PMID: 26589654
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM, Aerts J, van den Heuvel M, Hiltermann TJN, Bahce I, Smit EF, Dingemans AC, Hendriks LE, Stigt JA, Schramel FMNH, van Tinteren H, Groen HJM; all participants of NVALT Immunotherapy Register (see addendum). Smit HJM, et al. Lung Cancer. 2020 Feb;140:107-112. doi: 10.1016/j.lungcan.2019.12.011. Epub 2019 Dec 28. Lung Cancer. 2020. PMID: 31911323 Free article.
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Phernambucq EC, Biesma B, Smit EF, Paul MA, vd Tol A, Schramel FM, Bolhuis RJ, Postmus PE. Phernambucq EC, et al. Among authors: schramel fm. Br J Cancer. 2006 Aug 21;95(4):470-4. doi: 10.1038/sj.bjc.6603289. Epub 2006 Aug 8. Br J Cancer. 2006. PMID: 16909132 Free PMC article. Clinical Trial.
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).
Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, Termeer A, Schlosser NJ, Debruyne C, Curran D, Giaccone G. Van Zandwijk N, et al. J Clin Oncol. 2000 Jul;18(14):2658-64. doi: 10.1200/JCO.2000.18.14.2658. J Clin Oncol. 2000. PMID: 10894864 Clinical Trial.
116 results